Atezolizumab

First-in-human trial of intratumoral injection of SYNB1891

Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy

IMvigor130: OS data for atezolizumab plus chemo versus chemo alone

Key findings on atezolizumab for mUC from IMvigor130

Factors impacting response to ICIs in mUC

Patterns of relapse after radiotherapy in SCLC and future treatment strategies

Encouraging developments in triple negative breast cancer immunotherapy

Checkpoint inhibitors for metastatic urothelial cancer

Combining chemotherapy and immunotherapy: key trials in lung cancer

Treatment advances in TNBC

Combining immunotherapy and radiotherapy to improve mesothelioma outcomes

Neoadjuvant atezolizumab for non-metastatic urothelial cancer

Advances in perioperative immunotherapy in lung cancer

LCMC3 primary analysis: Neoadjuvant atezolizumab in NSCLC

ASCO GI: updates in KEYNOTE-177, IMbrave150 & ClarIDHy

Key updates in bladder cancer from ASCO GU 2021